Evaluation of clinical and echographic parameters of patients with benign prostatic hyperplasia
Keywords:
men´s health cares; benign disease; echography; exams; pathology; prostate.Abstract
Introduction: Benign prostatic hyperplasia (BPH) is considered a non-malignant pathology; a common disease whose incidence increases with age.
Objective: To characterize patients with benign prostatic hyperplasia according to clinical and echographic variables of interest.
Methods: A basic, descriptive research was carried out, with a mixed, cross-sectional and observational approach of a serial cases consisting of 12 patients diagnosed with benign prostatic hyperplasia. Clinical and ultrasound variables were used, with methods such as observation, logical history and documentary review. The governing institution has been the Emilio Bárcena combatants polyclinic, in Santiago de Cuba province, represented by the Imaging department. The duration of the study was from January to June, 2024.
Results: In the investigation there was a prevalence of patients who were in the age group of 60 to 69 years. The clinical manifestations were, first, nycturia followed by dysuria, according to the degree of severity. The echographic description was taken into account with prevalence of grade II lesions.
Conclusions: In our environment, benign prostatic hyperplasia is common in the sixth decade of life, with dysuric manifestations and low degree of severity from the echographic point of view.
Downloads
References
1.Silva HA, Souza JA. Vulnerabilidad de pacientes con hiperplasia prostática tratados con dutasterida y finasterida. Revista Bioética. 2021 [citado 4/07/2021];29(2):394-400. Disponible en: http://www.scielo.br/j/bioet/a/rCdtn46skZFBGKmvQWKNc7J/?format=pdf&lang=es
2. López Angulo DE, Castro Rivera E del C, Alfaro Arguedas HD. Revisión actual del Diagnóstico, tratamiento médico y quirúrgico en Hiperplasia Prostática Benigna. LATAM Revista Latinoamericana de Ciencias Sociales y Humanidades. 20234[citado 4/09/2024];4(2),2281-92. Disponible en: https://latam.redilat.org/index.php/lt/article/view/756/1027
3. Ninamango Safora MN. Factores de riesgo asociados a hiperplasia benigna de próstata en pacientes del Hospital Regional Docente Clínico Quirúrgico Daniel Alcides Carrión - Huancayo, 2021. [Tesis]. Huancayo-Perú: Universidad Continental; 2022. [citado 4/08/2024].80p. Disponible: https://repositorio.continental.edu.pe/bitstream/20.500.12394/12469/1/IV_FCS_508_TE_Ninamango_Safora_2022.pdf
4. Barboza Hernández M. Hiperplasia Prostática Benigna. Revista Médica Sinergia. 2017[citado 9/11/2021]:2(8);11-6. Disponible en: https://www.medigraphic.com/pdfs/sinergia/rms-2017/rms178c.pdf
5. Astudillo Sánchez MV, Reinoso Martínez LA, Veloz Espinoza MB, Soria Barrionuevo NE. Hipertrofia prostática, diagnóstico por imagen y actualización en el tratamiento clínico quirúrgico. RECIAMUC. 2024[citado 12/05/2025];8(2):446-50. Disponible en: https://reciamuc.com/index.php/RECIAMUC/article/view/1407/2219
6. Sandoval Gutiérrez JA, Fonseca Andrade JE, Bautista Frausto JH, Mora Vázquez CA. Hiperplasia prostática benigna: artículo de revisión. Ciencia Latina Revista Multidisciplinar. 2022[citado 12/05/2025];6(2):423-38. Disponible en: https://ciencialatina.org/index.php/cienciala/article/view/1893/2698
7. Jiménez González B, López Balderas NA, Torres Hernández RM, Hernández Ojeda H, Rodríguez Artigas C. Factores relacionados con hiperplasia prostática en pacientes de la UMAE No.14 IMSS. Veracruz. Rev Inves Cien Sal. 2023 [citado 15/05/2025];18(1):46-52. Disponible en: https://www.imbiomed.com.mx/articulo.php?id=117765
8. Pérez Medina LF, Becerra Anaya JM, Delegada Mejía GR. Complicaciones posoperatorias en pacientes con hiperplasia benigna de próstata según técnica quirúrgica. Rev Cub Med Mil. 2021 [citado 06/10/2024];50(4). Disponible en: http://scielo.sld.cu/pdf/mil/v50n4/1561-3046-mil-50-04-e1615.pdf
9. Conchado Martínez J, Álvarez Ochoa R, Serrano Guevara CH. Hiperplasia prostática benigna y síntomas del tracto urinario inferior. Revista Cubana de Medicina General Integral. 2021[citado 25/06/2025];37(1):e1310. Disponible: http://scielo.sld.cu/pdf/mgi/v37n1/1561-3038-mgi-37-01-e1310.pdf
10. Aurelio León Estrada. Flujometría manual en la evaluación clínica y terapéutica de pacientes con hiperplasia prostática benigna. 2022 [citado 25/06/2025];26(4):e3309. Disponible: http://scielo.sld.cu/pdf/san/v26n4/1029-3019-san-26-04-e3309.pdf
11.Yazdi H, Restrepo C, Foltz C, Hammand M, Chung PH, Gomella LG, et al. Symptomatic Bening Prostatic Hyperplasia. J Bone Jt Surg. 2020[citado14/05/2021];102(7):543-9. Disponible en: https://journals.lww.com/jbjsjournal/abstract/2020/04010/symptomatic_benign_prostatic_hyperplasia__a_risk.1.aspx
12. Autran Gómez AM, Torres Hernández RM, Hernández Ojeda H, Silva Cañetas CS, García Aguilar MF, Castellanos Hernández JA, Pavón Pérez LB. Relación diagnóstica del ultrasonido y el antígeno prostático específico en pacientes con hiperplasia prostática. Rev Invest Cien Sal. 2023[citado 10/09/2024]:18(2): 47-52. Disponible en: https://www.imbiomed.com.mx/articulo.php?id=118441
13. Ortiz Colorado ME, Bueno Ordóñez S, Urquiaga Melquiades DT. Características clínicas y epidemiológicas de pacientes con hiperplasia prostática benigna Sintomática en el hospital regional docente de Cajamarca, 2018. Rev med Trujillo. 2021 [citado 10/09/2024];16(2):98-103. Disponible en: https://revistas.unitru.edu.pe/index.php/RMT/article/view/3631/4309
14. Quispe Remuzgo R. Prevalencia de hiperplasia prostática benigna en pacientes atendidos del servicio de urología – hospital militar central. [Tesis]. Huancayo-Perú: Universidad Roosevelt; 2022[citado 4/08/2024].40p. Disponible en: https://repositorio.uroosevelt.edu.pe/bitstream/handle/20.500.14140/977/TESIS%20PROSTATITIIS.pdf?sequence=1&isAllowed=y
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 MEDISAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
